The success rates of drugs during various phases of the clinical development pipeline are crucial benchmarks for valuation models in the pharmaceutical investment community.
With central research and development funding at an all-time low in the United States [1], early biotech investors tend to target low investment projects with the expectation of a 30× return from their few successful ventures.
Wednesday, March 19, 2014
Although biotechnology investors and preclinical pharmacology
experts may not always concur, peptide therapeutics offer
demonstrable commercial success [1]. More than 50 peptide
drugs, with annual sales in excess of $1 billion each, were marketed
...